..
Soumettre le manuscrit arrow_forward arrow_forward ..

Targeting the PI3K/Akt/mTOR Signaling Pathway in Colorectal Cancer Treatment: Current Insights and Future Perspectives

Abstract

Johannes Christian

Colorectal Cancer (CRC) remains a significant global health burden, necessitating the development of novel therapeutic strategies. The PI3K/Akt/ mTOR signaling pathway has emerged as a promising target in CRC due to its pivotal role in regulating cell proliferation, survival, and metabolism. This article provides a comprehensive overview of the dysregulation of the PI3K/Akt/mTOR pathway in CRC and discusses the therapeutic potential of targeting this pathway for CRC treatment. We explore the preclinical and clinical evidence supporting the efficacy of PI3K/Akt/mTOR inhibitors in CRC, highlighting ongoing challenges and future directions in harnessing this pathway for improved patient outcomes.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié

Partagez cet article

arrow_upward arrow_upward